SIRT1 Activators Suppress Inflammatory Responses through Promotion of p65 Deacetylation and Inhibition of NF-κB Activity

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Yang, Hongying ^a   Zhang, Wei ^b   Pan, Heng ^b   Feldser, Heidi G ^a   Lainez, Elden ^a   Miller, Christine ^a   Leung, Stewart ^b   Zhong, Zhong ^b   Zhao, Huizhen ^a   Sweitzer, Sharon ^a   Considine, Thomas ^a   Riera, Thomas ^a   Suri, Vipin ^a   White, Brian ^a   Ellis, James L ^a   Vlasuk, George P ^a   Loh, Christine ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; SIRTUIN 1; SRTCD 1023; SRTCE 1022; SRTCL 1015; SRTCX 1002; SRTCX 1003; SRTCZ 1001; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEACETYLATION; DOSE RESPONSE; DOWN REGULATION; IC 50; IN VITRO STUDY; INFLAMMATION; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

ACETYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZIMIDAZOLES; CELL LINE; HUMANS; INFLAMMATION; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SIRTUIN 1; SMALL MOLECULE LIBRARIES; THIAZOLES; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866986715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046364     Document Type: Article

References (65)

1. Chung HY, Lee EK, Choi YJ, Kim JM, Kim DH, et al. (2011) Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. J Dent Res 90: 830-840.
2. Goh FG, Midwood KS, (2012) Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford) 51: 7-23.
3. Viatour P, Merville MP, Bours V, Chariot A, (2005) Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43-52.
4. Ishinaga H, Jono H, Lim JH, Kweon SM, Xu H, et al. (2007) TGF-beta induces p65 acetylation to enhance bacteria-induced NF-kappaB activation. EMBO J 26: 1150-1162.
5. Yang XD, Huang B, Li M, Lamb A, Kelleher NL, et al. (2009) Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J 28: 1055-1066.
6. Ghizzoni M, Haisma HJ, Maarsingh H, Dekker FJ, (2011) Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation. Drug Discov Today 16: 504-511.
7. Chen LF, Mu Y, Greene WC, (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21: 6539-6548.
8. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758-2766.
9. Rothgiesser KM, Fey M, Hottiger MO, (2010) Acetylation of p65 at lysine 314 is important for late NF-kappaB-dependent gene expression. BMC Genomics 11: 22.
10. Buerki C, Rothgiesser KM, Valovka T, Owen HR, Rehrauer H, et al. (2008) Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res 36: 1665-1680.
11. Chen L, Fischle W, Verdin E, Greene WC, (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657.
12. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, et al. (1998) Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 273: 29291-29294.
13. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, et al. (1999) Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19: 6367-6378.
14. Zhong H, May MJ, Jimi E, Ghosh S, (2002) The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9: 625-636.
15. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J 23: 2369-2380.
16. Haigis MC, Sinclair DA, (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295.
17. Baur JA, (2010) Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 131: 261-269.
18. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, et al. (2005) SIRT1 protects against microglia-dependent beta amyloid toxicity through inhibiting NF-kappa B signaling. J Biol Chem.
19. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A, et al. (2007) Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 292: L567-576.
20. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I, (2008) SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 861-870.
21. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH, (2008) Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 105: 9793-9798.
22. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, et al. (2010) Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol Cell Biol 30: 4712-4721.
23. Kim EJ, Kho JH, Kang MR, Um SJ, (2007) Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 28: 277-290.
24. Kim JE, Chen J, Lou Z, (2008) DBC1 is a negative regulator of SIRT1. Nature 451: 583-586.
25. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, et al. (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451: 587-590.
26. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, et al. (2008) Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3: 158-167.
27. Revollo JR, Grimm AA, Imai S, (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763.
28. Kang H, Jung JW, Kim MK, Chung JH, (2009) CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 4: e6611.
29. Guo X, Williams JG, Schug TT, Li X, (2010) DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem 285: 13223-13232.
30. Gerhart-Hines Z, Dominy JE Jr, Blattler SM, Jedrychowski MP, Banks AS, et al. (2011) The cAMP/PKA Pathway Rapidly Activates SIRT1 to Promote Fatty Acid Oxidation Independently of Changes in NAD(+). Mol Cell 44: 851-863.
31. Escande C, Chini CC, Nin V, Dykhouse KM, Novak CM, et al. (2010) Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest 120: 545-558.
32. Yoshino J, Mills KF, Yoon MJ, Imai S, (2011) Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14: 528-536.
33. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
34. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
35. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
36. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, et al. (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15: 675-690.
37. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, et al. (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29: 1363-1374.
38. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, et al. (2010) SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298: E419-428.
39. Smith JJ, Kenney RD, Gagne DJ, Frushour BP, Ladd W, et al. (2009) Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 3: 31.
40. Yamazaki Y, Usui I, Kanatani Y, Matsuya Y, Tsuneyama K, et al. (2009) Treatment with SRT1720, a SIRT1 Activator, Ameliorates Fatty Liver with Reduced Expression of Lipogenic Enzymes in MSG Mice. Am J Physiol Endocrinol Metab.
41. Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, et al. (2011) SRT1720 improves survival and healthspan of obese mice. Sci Rep 1.
42. Vu C, Disch JS, Ng PY, Blum CA, Perni RB (2010) Benzimidazoles and Related Analogs as Sirtuin Modulators. World Intellectual Property Organization Patent WO 2010/003048.
43. Disch JS, Vu CB, McPherson L, Ng PY, Bemis JE, et al. (2010) 2-Aryl-Benzimidazole-4-carboxamides as Novel SIRT1 Activators. 240th ACS National Meeting MEDI: 70.
44. Vu C, Oalmann C, White B, Perni RB (2010) Quinazolinone, Quinolone and Related Analogs as Sirtuin Modulators. World Intellectual Property Organization Patent WO 2010/037129.
45. Lysko PG, Weinstock J, Webb CL, Brawner ME, Elshourbagy NA, (1999) Identification of a small-molecule, nonpeptide macrophage scavenger receptor antagonist. J Pharmacol Exp Ther 289: 1277-1285.
46. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28-38.
47. Robers MB, Loh C, Carlson CB, Yang H, Frey EA, et al. (2011) Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen(R) technology. Mol Biosyst 7: 59-66.
48. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
49. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
50. Yang XD, Tajkhorshid E, Chen LF, (2010) Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB. Mol Cell Biol 30: 2170-2180.
51. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, et al. (2005) Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 312: 373-381.
52. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, et al. (2005) NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 25: 7966-7975.
53. Yang B, Trump RP, Shen Y, McNulty JA, Clifton LG, et al. (2008) RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice. BMC Pharmacol 8: 7.
54. van der Poll T, Jansen PM, Montegut WJ, Braxton CC, Calvano SE, et al. (1997) Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol 158: 1971-1975.
55. Manabe I, (2011) Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 75: 2739-2748.
56. Aulakh R, Singh S, (2008) Strategies for minimizing corticosteroid toxicity: a review. Indian J Pediatr 75: 1067-1073.
57. Camu F, Lauwers MH, Vanlersberghe C, (1996) Side effects of NSAIDs and dosing recommendations for ketorolac. Acta Anaesthesiol Belg 47: 143-149.
58. Tang BL, (2011) Sirt1's systemic protective roles and its promise as a target in antiaging medicine. Transl Res 157: 276-284.
59. Satoh A, Stein L, Imai S, (2012) The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol 206: 125-162.
60. Rothgiesser KM, Erener S, Waibel S, Luscher B, Hottiger MO, (2010) SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 123: 4251-4258.
61. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, et al. (2009) SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 136: 62-74.
62. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, et al. (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140: 280-293.
63. Zhang J, Lee SM, Shannon S, Gao B, Chen W, et al. (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119: 3048-3058.
64. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, et al. (2011) Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol 31: 1022-1029.
65. van der Meer AJ, Scicluna B, Lin J, Jacobson EW, Vlasuk GP, et al. (2011) The first demonstration of clinical activity by a small molecule SIRT1 activator: SRT2104 reduces cytokine release and coagulation activation in a human endotoxemia model. Inflamm Res 60: S82.